Phase III data show Roche ’s Port Delivery System with ranibizumab enabled over 98% of patients to go six months between treatments for neovascular age-related macular degeneration
Basel, 22 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced detailed results from the phase III Archway study evaluating its investigational Port Delivery System with ranibizumab (PDS) for the treatment of neovascular or “wet” age-related macular degeneration (nAMD), a leading cause of blindness globally.1 In Archway, 98.4% of PDS patients were able to go six months without needing additional treatment and achieved vision outcomes equivalent to patients receiving monthly ranibizumab eye injections, a current standard of care. In the study, PDS was generally well-tolerated, with a favourable benefit...
Source: Roche Media News - July 22, 2020 Category: Pharmaceuticals Source Type: news

Phase III data show Roche ’s Port Delivery System with ranibizumab enabled over 98% of patients to go six months between treatments for neovascular age-related macular degeneration
Basel, 22 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced detailed results from the phase III Archway study evaluating its investigational Port Delivery System with ranibizumab (PDS) for the treatment of neovascular or “wet” age-related macular degeneration (nAMD), a leading cause of blindness globally.1 In Archway, 98.4% of PDS patients were able to go six months without needing additional treatment and achieved vision outcomes equivalent to patients receiving monthly ranibizumab eye injections, a current standard of care. In the study, PDS was generally well-tolerated, with a favourable benefit...
Source: Roche Investor Update - July 22, 2020 Category: Pharmaceuticals Source Type: news

Regeneron Funneled Kickbacks Through a Patient Charity, Federal Lawsuit Claims
The case is the latest inquiry into pharmaceutical companies ’ donations to patient assistance charities, which have been blamed for inflating the cost of drugs. (Source: NYT Health)
Source: NYT Health - June 24, 2020 Category: Consumer Health News Authors: Katie Thomas Tags: Regeneron Pharmaceuticals Inc Eylea (Drug) Drugs (Pharmaceuticals) Suits and Litigation (Civil) Bribery and Kickbacks Avastin (Drug) Lucentis (Drug) Nonprofit Organizations Chronic Disease Fund Genentech Inc your-feed-healthcare Source Type: news

Roche ’s Port Delivery System with ranibizumab shows positive phase III results in neovascular age-related macular degeneration
Basel, 27 May 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from the phase III Archway study, evaluating Port Delivery System with ranibizumab (PDS) in people living with neovascular or “wet” age-related macular degeneration (nAMD). PDS is a permanent refillable eye implant, approximately the size of a grain of rice, which continuously delivers a customised formulation of ranibizumab over a period of months. The Archway trial met its primary endpoint, demonstrating that patient s with PDS who received refills every six months achieved visual acuity outcomes equivalent to tho...
Source: Roche Media News - May 27, 2020 Category: Pharmaceuticals Source Type: news

Roche ’s Port Delivery System with ranibizumab shows positive phase III results in neovascular age-related macular degeneration
Basel, 27 May 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from the phase III Archway study, evaluating Port Delivery System with ranibizumab (PDS) in people living with neovascular or “wet” age-related macular degeneration (nAMD). PDS is a permanent refillable eye implant, approximately the size of a grain of rice, which continuously delivers a customised formulation of ranibizumab over a period of months. The Archway trial met its primary endpoint, demonstrating that patient s with PDS who received refills every six months achieved visual acuity outcomes equivalent to tho...
Source: Roche Investor Update - May 27, 2020 Category: Pharmaceuticals Source Type: news

Novel Anti-VEGF Delivery System Aims to Reshape AMD Treatment Novel Anti-VEGF Delivery System Aims to Reshape AMD Treatment
Early results highlight the promise of a permanent, refillable port implant, which allows sustained delivery of ranibizumab.Medscape Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 21, 2020 Category: Consumer Health News Tags: Ophthalmology Viewpoint Source Type: news

Treat-and-Extend Approach With Ranibizumab Effective in AMD Treat-and-Extend Approach With Ranibizumab Effective in AMD
In patients with neovascular age-related macular disease, a treat-and-extend ranibizumab regimen is not inferior to injections given at fixed intervals, plus it's more convenient, according to a new clinical trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 23, 2020 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Ranibizumab, Aflibercept Both Effective for Diabetic Macular Edema in Real World Ranibizumab, Aflibercept Both Effective for Diabetic Macular Edema in Real World
Both ranibizumab and aflibercept effectively treat diabetic macular edema (DME), one-year data from a registry study reveal.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 11, 2019 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Intravitreous Ranibizumab Cost-Effective for Some With Proliferative Diabetic Retinopathy Intravitreous Ranibizumab Cost-Effective for Some With Proliferative Diabetic Retinopathy
At five years, intravitreous ranibizumab therapy for proliferative diabetic retinopathy (PDR) appears to be cost-effective relative to panretinal photocoagulation (PRP), but only in eyes with vision-impairing center-involved diabetic macular edema (CI-DME), according to new findings.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 6, 2019 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Novartis nabs FDA priority review for potential eye blockbuster
If approved this will have the drugmaker go head to head against Roche ’s Lucentis and Regeneron’s Eylea (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - April 16, 2019 Category: Pharmaceuticals Source Type: news

Ranibizumab and Aflibercept Prompt Comparable Visual Gain in AMD Ranibizumab and Aflibercept Prompt Comparable Visual Gain in AMD
In patients with neovascular age-related macular degeneration (nAMD), aflibercept and ranibizumab achieve similar average visual acuity increases, according Australian researchers.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 31, 2019 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Panretinal photocoagulation may increase diabetic macular oedema risk
Research, published inThe American Journal of Clinical Nutrition, suggests that treatment of proliferative diabetic retinopathy with panretinal photocoagulation, rather than ranibizumab injections, may increase the risk of diabetic macular oedema.Healio (Source: Society for Endocrinology)
Source: Society for Endocrinology - December 17, 2018 Category: Endocrinology Source Type: news

Genentech touts data for refillable eye implant in wet-AMD trial
Roche‘s (OTC:RHHBY) Genentech touted additional positive data last week from a Phase II study of its Port Delivery System, a refillable eye implant designed to deliver ranibizumab to treat wet age-related macular degeneration. The company first reported top-line results from the Phase II Ladder study in July. The implant is intended to allow wet-AMD patients to go for months without needing to see an ophthalmologist for treatment; the current standard of care for wet-AMD patients involves monthly injections of therapy. Get the full story at our sister site, Drug Delivery Business News. The post Ge...
Source: Mass Device - October 29, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Wall Street Beat Genentech Roche Source Type: news

Two Treatments, Similar Outcomes in Diabetic Retinopathy
(MedPage Today) -- Visual acuity similar at 5 years with ranibizumab, photocoagulation (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - October 17, 2018 Category: Endocrinology Source Type: news

Avastin/Lucentis/Eylea ruling good news for patients, says RPS
Responding to news that the NHS will allow Avastin to be prescribed for age related wet macular degeneration, RPS President Ash Soni said:“This is a landmark ruling and good news for patients (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - September 21, 2018 Category: Drugs & Pharmacology Source Type: news

Implant Poised to Transform Macular Degeneration Treatment Implant Poised to Transform Macular Degeneration Treatment
A system that delivers ranibizumab without injections could be a turning point for patients with neovascular age-related macular degeneration, results from the highly anticipated LADDER trial show.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 27, 2018 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Reminder: Invitation to Roche's Virtual Pipeline Event: Phase 2 LADDER results of the Port Delivery System (PDS) with Lucentis to be presented at the 2018 ASRS annual meeting
We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Thursday, 2 August 2018, featuring data from the Phase 2 LADDER study of the Port Delivery System (RPDS) with Lucentis to be presented at the American Society of Retina Specialists (ASRS) annual meeting (20-25 July 2018) in Vancouver, Canada. (Source: Roche Investor Update)
Source: Roche Investor Update - July 27, 2018 Category: Pharmaceuticals Source Type: news

Laser, Anti-VEGF Therapy Similar for DME
(MedPage Today) -- Ranibizumab advantage at 2 years lost at 5 (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - July 25, 2018 Category: Primary Care Source Type: news

Genentech touts positive data for tiny, refillable eye implant
Roche‘s (OTC:RHHBY) Genentech touted positive top-line data today from a Phase II study of its Port Delivery System, an eye implant designed to administer a sustained dose of ranibizumab in patients with wet age-related macular degeneration. The refillable device, which is roughly the size of a grain of rice, is intended to enable wet-AMD patients to go for months without needing to see an ophthalmologist for treatment. The current standard of care for wet-AMD involves monthly injections of anti-vascular endothelial growth factor therapy. Get the full story at our sister site, Drug Delivery Business Ne...
Source: Mass Device - July 25, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Wall Street Beat Genentech Roche Source Type: news

Invitation to Roche's Virtual Pipeline Event: Phase 2 LADDER results of the Port Delivery System (PDS) with Lucentis to be presented at the 2018 ASRS annual meeting
We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Thursday, 2 August 2018, featuring data from the Phase 2 LADDER study of the Port Delivery System (RPDS) with Lucentis to be presented at the American Society of Retina Specialists (ASRS) annual meeting (20-25 July 2018) in Vancouver, Canada. (Source: Roche Investor Update)
Source: Roche Investor Update - July 11, 2018 Category: Pharmaceuticals Source Type: news

FDA approves Lucentis (ranibizumab injection) 0.3 mg prefilled syringe for diabetic macular edema and diabetic retinopathy
Roche today announced that the U.S. Food and Drug Administration (FDA) approved the Lucentis ® (ranibizumab injection) 0.3 mg prefilled syringe (PFS) as a new method of administering the medicine to treat all forms of diabetic retinopathy. (Source: Roche Investor Update)
Source: Roche Investor Update - March 22, 2018 Category: Pharmaceuticals Source Type: news

Genentech ’ s pre-filled syringe for diabetic retinopathy wins FDA nod
Roche‘s (OTC:RHHBY) Genentech announced today that the FDA approved its 0.3-mg pre-filled syringe as a new way to administer Lucentis to diabetic retinopathy patients. The company’s drug is the only FDA-approved medicine indicated for the treatment of diabetic retinopathy. The 0.3-mg pre-filled syringe is the first device of its kind approved to deliver an anti-vascular endothelial growth factor agent to patients with diabetic retinopathy and diabetic macular edema. Get the full story at our sister site, Drug Delivery Business News. The post Genentech’s pre-filled syringe for diabetic retinopath...
Source: Mass Device - March 21, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Optical/Ophthalmic Pharmaceuticals Regulatory/Compliance Wall Street Beat Genentech Roche Source Type: news

FDA Approves Genentech ’s Lucentis (ranibizumab injection) 0.3 mg Prefilled Syringe for Diabetic Macular Edema and Diabetic Retinopathy
South San Francisco, CA -- March 21, 2018 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved the Lucentis (ranibizumab injection) 0.3 mg prefilled syringe... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 21, 2018 Category: Drugs & Pharmacology Source Type: news

893716 893716
Biomarkers from the anterior chamber of the eye help predict response to ranibizumab, which could spare patients repeated injections with an ineffective agent, a small trial suggested.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 9, 2018 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Biomarkers May Predict Rx Response in Diabetic Macular Edema Biomarkers May Predict Rx Response in Diabetic Macular Edema
Biomarkers from the anterior chamber of the eye help predict response to ranibizumab, which could spare patients repeated injections with an ineffective agent, a small trial suggested.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 9, 2018 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Repeated Ranibizumab Injections Safe in Diabetic Macular Edema Repeated Ranibizumab Injections Safe in Diabetic Macular Edema
In patients with diabetic macular edema, repeated ranibizumab injections are not associated with impaired macular perfusion and can be safely offered even to those with severe microangiopathy and advanced capillary dropout, researchers say.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 8, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Ranibizumab Safe, Effective for Macular Edema Due to Uncommon Causes Ranibizumab Safe, Effective for Macular Edema Due to Uncommon Causes
Ranibizumab 0.5 mg is safe and effective for patients with macular edema (ME) that is not due to diabetes, retinal vein occlusion (RVO) or neovascular age-related macular degeneration (nAMD), according to findings from the PROMETHEUS randomized trial.Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - February 28, 2018 Category: Opthalmology Tags: Ophthalmology News Source Type: news

Anti-VEGF Agents Improve Vision Despite Ongoing Diabetic Macular Edema Anti-VEGF Agents Improve Vision Despite Ongoing Diabetic Macular Edema
In patients with diabetic macular edema (DME), aflibercept and ranibizumab are more effective than bevacizumab in preventing disease persistence, but each drug can lead to substantial gains in vision, according to a post hoc analysis of a randomized trial.Reuters Health Information (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - February 14, 2018 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Low-dose Ranibizumab Effective for Retinopathy of Prematurity Low-dose Ranibizumab Effective for Retinopathy of Prematurity
Low doses of anti-VEGF therapy with ranibizumab are effective in infants with retinopathy of prematurity (ROP), according to results from the CARE-ROP study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 9, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Ohr Pharmaceutical shares plummet after eye drug fails in wet-AMD trial
Shares in Ohr Pharmaceutical (NSDQ:OHRP) dropped -83% to trade at 35¢ apiece this morning after the company revealed that its topical therapy did not meet the primary endpoint of a trial evaluating its efficacy as a treatment for wet age-related macular degeneration. The company’s Mako study randomized patients 1:1 to receive either Ohr’s topical, twice-daily squalamine therapy in combination with monthly Lucentis injections or a placebo combined with Lucentis. Get the full story at our sister site, Drug Delivery Business News. The post Ohr Pharmaceutical shares plummet after eye drug fails in we...
Source: Mass Device - January 5, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Optical/Ophthalmic Pharmaceuticals Wall Street Beat ohrpharmaceutical Source Type: news

Dexamethasone Does Not Improve Vision in Persistent Diabetic Macular Edema Dexamethasone Does Not Improve Vision in Persistent Diabetic Macular Edema
Adding dexamethasone to continued ranibizumab treatment reduces retinal thickness but does not improve vision in patients with persistent diabetic macular edema (DME), according to results from a phase 2 randomized trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 21, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Taxpayers pay twice for crucial drugs like Avastin | Letters
Big pharma companies are charging over the odds for medicines developed with public funding, writeHeidi Chow andTabitha HaIt is shocking, but not surprising, that big drugs companies are threatening to sue the NHS for using cheaper versions of drugs that could save people from going blind (Drug firms trying to stop cheap eye treatment on NHS, 1 November). Another part of this story is that the two medicines in question – Lucentis (known generically as ranibizumab) and Avastin (bevacizumab) are based on the groundbreaking discovery of monoclonal antibodies, whichwere developed with UK public funding.The NHS itself fun...
Source: Guardian Unlimited Science - November 5, 2017 Category: Science Authors: Letters Tags: NHS Drugs Medical research Science Health Society Pharmaceuticals industry Business Blindness and visual impairment Disability Source Type: news

Policy and regulation stand in the way of NHS use of unlicensed eye injection drug with potential to save millions of pounds
Eye injection drugs recommended by NICE cost the NHS up to £ 447 million annually, but could be replaced by an unlicensed drug, bevacizumab, costing as much as ten times less. Use of the two licensed drugs, ranibizumab and aflibercept, has increased three-fold over the last five years, with some parts of England treating five times as many patients as others. (Source: University of Bristol news)
Source: University of Bristol news - November 1, 2017 Category: Universities & Medical Training Tags: Health, Research; Faculty of Health Sciences, Faculty of Health Sciences, Bristol Medical School, Faculty of Health Sciences, Population Health Sciences; Press Release Source Type: news

Ranibizumab Beats Laser for Diabetic Retinopathy Ranibizumab Beats Laser for Diabetic Retinopathy
New trial findings are challenging the standard of care for diabetic retinopathy and are opening the door to wider use of anti-vascular endothelial growth factor drugs.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 11, 2017 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Analysis Favors Aflibercept for Diabetic Macular Edema Analysis Favors Aflibercept for Diabetic Macular Edema
Aflibercept appears to be more effective than ranibizumab, with or without laser photocoagulation, in a new meta-analysis of treatments for diabetic macular edema.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 10, 2017 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Opthea touts data from wet-AMD trial
Opthea (ASX:OPT) touted additional data today from the Phase I/IIa trial of its wet age-related macular degeneration therapy, OPT-302. The 50-patient Phase I/IIa trial recruited participants who were either treatment-naive or previously treated with an intravitreal anti-VEGF therapy. Researchers evaluated OPT-302 as a monotherapy and in combination with Lucentis (ranibizumab). Get the full story at our sister site, Drug Delivery Business News. The post Opthea touts data from wet-AMD trial appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - August 15, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Wall Street Beat Opthea Source Type: news

Aflibercept May Be Effective for Resistant Exudative AMD Aflibercept May Be Effective for Resistant Exudative AMD
Aflibercept appears to improve outcomes in patients with exudative age-related macular degeneration (AMD) resistant to treatment with ranibizumab or bevacizumab, researchers from Norway report.Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - June 14, 2017 Category: Opthalmology Tags: Ophthalmology News Source Type: news

Minimal Differences Between Anti-VEGF Drugs on IOP Over Time Minimal Differences Between Anti-VEGF Drugs on IOP Over Time
Patients on anti-VEGF therapy may have a small decrease in intraocular pressure (IOP) over time, but with minimal differences between aflibercept, ranibizumab, and bevacizumab, a new large study suggests.Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - June 1, 2017 Category: Opthalmology Tags: Ophthalmology News Source Type: news

FDA approves Roche ’s Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States
Roche today announced that the US Food and Drug Administration (FDA) approved Lucentis ® (ranibizumab injection) 0.3 mg for the monthly treatment of withal forms of diabetic retinopathy. (Source: Roche Media News)
Source: Roche Media News - April 18, 2017 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States
Roche today announced that the US Food and Drug Administration (FDA) approved Lucentis ® (ranibizumab injection) 0.3 mg for the monthly treatment of withal forms of diabetic retinopathy. (Source: Roche Investor Update)
Source: Roche Investor Update - April 18, 2017 Category: Pharmaceuticals Source Type: news

FDA OKs Ranibizumab for All Forms of Diabetic Retinopathy FDA OKs Ranibizumab for All Forms of Diabetic Retinopathy
The VEFG inhibitor had been approved just for diabetic retinopathy accompanied by diabetic macular edema, in addition to other eye disorders.FDA Approvals (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - April 18, 2017 Category: Endocrinology Tags: Ophthalmology News Alert Source Type: news

FDA Approves Genentech ’s Lucentis (ranibizumab) for all Forms of Diabetic Retinopathy
South San Francisco, CA -- April 17, 2017 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Lucentis ® (ranibizumab injection) 0.3 mg for the monthly... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 17, 2017 Category: Drugs & Pharmacology Source Type: news

Cardiovascular Safety of Ranibizumab for Diabetic Macular Edema Still Unclear Cardiovascular Safety of Ranibizumab for Diabetic Macular Edema Still Unclear
Uncertainty lingers about the cardiovascular safety of intravitreal ranibizumab injections for diabetic macular edema, a pooled analysis of clinical trials shows.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 12, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Opthea gets positive feedback from European regulatory groups for wet-AMD injection
Opthea (ASX:OPT) said today that it received positive feedback from meetings with the U.K.’s Medicines and Healthcare Products Regulatory Agency and Sweden’s Medical Products Agency over its OPT-302 therapy for the treatment of wet age-related macular degeneration. The Australia-based company’s OPT-302 therapy consists of a soluble form of vascular endothelial growth factor receptor 3 that blocks the activity of 2 proteins that cause blood vessels to grow and leak. It is being evaluated in a phase 1/2 clinical trial in patients with wet AMD as a monotherapy and with ranibizumab, delivered as monthly intra...
Source: Mass Device - March 20, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Optical/Ophthalmic Regulatory/Clearance Wall Street Beat Opthea Source Type: news

Researchers develop micropump for patients with glaucoma
Researchers from the University of Southern California’s Roski Eye Institute developed a micropump that can be implanted directly into the eye and deliver a predetermined dose of the diabetic macular edema drug ranibizumab. Current treatments for glaucoma are traditionally delivered using eye drops. But studies show that some patients stop taking their prescription glaucoma eye drops after 1 year, according to the team of researchers. Patients can be uncomfortable using the eye drops or they forget to consistently take their prescribed medication. Get the full story at our sister site, Drug Delivery Busines...
Source: Mass Device - March 3, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Optical/Ophthalmic Research & Development Replenish Inc Source Type: news

Lucentis (Ranibizumab Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 27, 2017 Category: Drugs & Pharmacology Source Type: news